2026 · 1st Quarter (Jan 1 - Mar 31)

RARE DISEASE COMPANY COALITION

Filed by RARE DISEASE COMPANY COALITION.

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 20, 2026
Income: Not reported
Expenses: $110,000.00
Registrant: RARE DISEASE COMPANY COALITION
Client: RARE DISEASE COMPANY COALITION
Filing UUID: 58152791-04cf-4bd8-9968-e208c63b1965
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals

Literal federal measure citations: HR 1262, S 3302, S 932, HR 1762

TRD · Trade (domestic/foreign)

Proclamation 11020 - Section 232 Pharmaceutical Tariffs

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.